RE: Naloxone

Dear Provider,

The Oklahoma Health Care Authority (OHCA) is pleased to announce that SoonerCare now covers various naloxone products for members with no physician visit necessary. A standing order is now in place authorizing pharmacists practicing in a contracted pharmacy to initiate a prescription, dispense, and be reimbursed for naloxone for SoonerCare.

A pharmacist utilizing this standing order must:

- Dispense naloxone in one of the formulations listed on the order and provide appropriate supplies for administration;
- Maintain a copy of the standing order at the pharmacy;
- Designate the prescriber as the designated physician pursuant to the standing order;
- Comply with all Oklahoma State Board of Pharmacy requirements for prescription orders, labeling, recordkeeping, and counseling; and
- Provide additional resources on drug overdose and naloxone use to the patient. See standing order for resource examples.

If you have any questions regarding this change, please call the OHCA provider helpline at 800-522-0114.

Thank you for your continued service to Oklahoma's SoonerCare members.

Sincerely,

Traylor Rains
State Medicaid Director
**Naloxone HCl Dispensing Protocol**

This standing order authorizes pharmacists who maintain a current active license practicing in an Oklahoma licensed pharmacy which is located in Oklahoma to initiate a prescription and dispense a naloxone opioid antagonist formulation listed in this standing order.

Any prescription issued pursuant to this standing order must designate the eligible recipient as the patient, regardless of that eligible recipient's status as an individual, organization, agency, or other entity. Pharmacists utilizing this standing order to dispense naloxone products must:

- Maintain a copy of the standing order at the pharmacy.
- Designate the prescriber as the designated physician pursuant to the standing order.
- Comply with all Oklahoma State Board of Pharmacy requirements for prescription orders, labeling, recordkeeping, and counseling.
- Additional resources on drug overdose and naloxone use should be provided to the patient and are available from the Oklahoma State Department of Health (OSDH). Examples include but are not limited to the following URLs.

### Eligible Recipients

Pursuant to Title 63 O.S. 2-312.2, a pharmacist may prescribe and dispense naloxone to:
- a person who is at risk of experiencing an opioid-related drug overdose;
- a family member or friend of an at-risk person;
- a first responder; or
- a person who voluntarily requests naloxone and is in the position to assist a person at risk of experiencing an opioid-related drug overdose.

### Route(s) of Administration

<table>
<thead>
<tr>
<th>Intranasal</th>
<th>Injectable*</th>
</tr>
</thead>
<tbody>
<tr>
<td>▪ Naloxone Nasal Spray 4 mg</td>
<td>▪ Naloxone 0.4 mg/mL Injection 1 mL Single Dose Vial (SDV) or pre-filled syringe</td>
</tr>
<tr>
<td>▪ Naloxone Nasal Spray 8 mg</td>
<td>▪ Naloxone 1 mg/mL Injection Single Dose Vial (SDV) or pre-filled syringe</td>
</tr>
</tbody>
</table>

### Medication and Required Supplies for Administration†

- Naloxone 0.4 mg/mL Injection 1 mL Single Dose Vial (SDV) or pre-filled syringe
- Naloxone 1 mg/mL Injection Single Dose Vial (SDV) or pre-filled syringe
- Naloxone 5 mg/ 0.5 mL Injection

### Directions for Use

- **Intranasal:** Administer a single spray of naloxone in one nostril upon signs of opioid overdose. Call 911. If minimal or no response, may repeat using a new nasal spray with each dose every 2-3 minutes until EMS arrives.
- **Injectable:** Inject the entire solution of the vial or pre-filled syringe intramuscularly in shoulder or thigh. Call 911. If minimal or no response, may repeat every 2-3 minutes until EMS arrives.
- **Administer a single dose intramuscularly or subcutaneously into the outer thigh, through clothing if necessary. Call 911. If minimal or no response, may repeat using a new device every 2-3 minutes until EMS arrives.**

### Dispense Quantity

2 doses

### Naloxone Contraindications

A history of hypersensitivity to naloxone or any of the other ingredients
<table>
<thead>
<tr>
<th><strong>Patient Education</strong></th>
<th>Provide the patient with basic instruction and information including but not limited to education regarding the risk factors of overdose, signs of an overdose, overdose response steps, proper use of naloxone, and need for the comprehensive substance abuse medical treatment.</th>
</tr>
</thead>
</table>
| **Notes from OHCA**   | *Injectables must be dispensed with appropriate supplies for administration.  
*Naloxone products dispensed must be Food and Drug Administration (FDA) approved and covered by SoonerCare to be included in this standing order. Over-the-counter (OTC) naloxone products may also be covered when these guidelines are met. |

Dr. Clayton Morris, M.D.  
Medical Director  
Department of Mental Health and Substance Abuse Services  
NPI: 1104906700

May 1, 2023  
Standing Order Effective Date